Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WHO SOLIDARITY Germany: Remdesivir in hospitalized COVID-19 patients
2020-001549-38Phase 3Terminated
- Sponsor
- Gesundheit Nord
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Remdesivir + local standard of care with Local standard of care alone (2 arms). Primary endpoint: Primary: Clinical status at day 15 on 7-point ordinal scale. Started Apr 2020; status: terminated.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001549-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001549-38.